FutureChem Co.Ltd (220100) - Total Liabilities

Latest as of September 2025: ₩19.40 Billion KRW ≈ $13.15 Million USD

Based on the latest financial reports, FutureChem Co.Ltd (220100) has total liabilities worth ₩19.40 Billion KRW (≈ $13.15 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore FutureChem Co.Ltd (220100) cash conversion ratio to assess how effectively this company generates cash.

FutureChem Co.Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how FutureChem Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are FutureChem Co.Ltd's assets to evaluate the company's liquid asset resilience ratio.

FutureChem Co.Ltd Competitors by Total Liabilities

The table below lists competitors of FutureChem Co.Ltd ranked by their total liabilities.

Company Country Total Liabilities
Dong-A St
KO:170900
Korea ₩747.62 Billion
OVB Holding AG
XETRA:O4B
Germany €200.87 Million
Polyplex (Thailand) Public Company Limited
BK:PTL
Thailand ฿5.97 Billion
Blue Foundry Bancorp
NASDAQ:BLFY
USA $1.84 Billion
NovaBridge Biosciences
NASDAQ:NBP
USA $131.67 Million
Anhui Huaqi Environmental Protection Technology Co. Ltd.
SHE:300929
China CN¥951.06 Million
Namchow Chemical Industrial Co Ltd
TW:1702
Taiwan NT$17.91 Billion
Mangalam Cement Limited
NSE:MANGLMCEM
India Rs14.50 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down FutureChem Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of FutureChem Co.Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.47 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.38 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how FutureChem Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for FutureChem Co.Ltd (2016–2024)

The table below shows the annual total liabilities of FutureChem Co.Ltd from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 ₩20.04 Billion
≈ $13.58 Million
+124.71%
2023-12-31 ₩8.92 Billion
≈ $6.04 Million
-52.00%
2022-12-31 ₩18.58 Billion
≈ $12.59 Million
-23.91%
2021-12-31 ₩24.42 Billion
≈ $16.55 Million
-37.52%
2020-12-31 ₩39.08 Billion
≈ $26.49 Million
-24.91%
2019-12-31 ₩52.05 Billion
≈ $35.27 Million
+9.37%
2018-12-31 ₩47.59 Billion
≈ $32.25 Million
+440.85%
2017-12-31 ₩8.80 Billion
≈ $5.96 Million
+458.64%
2016-12-31 ₩1.58 Billion
≈ $1.07 Million
--

About FutureChem Co.Ltd

KQ:220100 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$274.64 Million
₩405.26 Billion KRW
Market Cap Rank
#15336 Global
#574 in Korea
Share Price
₩18340.00
Change (1 day)
-3.52%
52-Week Range
₩15200.00 - ₩34200.00
All Time High
₩34200.00
About

FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more